NK 611

Drug Profile

NK 611

Latest Information Update: 21 Aug 2007

Price : $50

At a glance

  • Originator Nippon Kayaku
  • Class Antineoplastics; Lignans; Tetrahydronaphthalenes
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Solid tumours

Most Recent Events

  • 02 Oct 2001 No-Development-Reported for Solid tumours in Japan (PO)
  • 20 Jul 1999 A clinical study has been added to the therapeutic trials, adverse events and pharmacokinetics sections
  • 01 Dec 1997 Suspended-I for Cancer in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top